<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215110</url>
  </required_header>
  <id_info>
    <org_study_id>TMC207-CL001</org_study_id>
    <nct_id>NCT01215110</nct_id>
  </id_info>
  <brief_title>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)</brief_title>
  <official_title>A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of TMC207 in Adult Patients With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral
      administration of TMC207 at multiple doses as determined by the rate of change of log10
      colony forming units (CFU) per ml sputum over the time period Day 7-14 in participants with
      smear positive pulmonary tuberculosis (TB). A control group will receive standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).</measure>
    <time_frame>Fourteen consecutive days of treatment</time_frame>
    <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 7-14).</measure>
    <time_frame>Days 7-14 of fourteen consecutive days of treatment</time_frame>
    <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Since Day 7 is later than the node day, the rate of change for this outcome is equal to the slope at Day 14. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).</measure>
    <time_frame>Days 2-14 of fourteen consecutive days of treatment</time_frame>
    <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).</measure>
    <time_frame>Two consecutive days of treatment</time_frame>
    <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Since this range (Days0-2) is before the node day, the rate of change for this outcome is equal to the slope at Day 0. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14)</measure>
    <time_frame>Fourteen consecutive days of treatment</time_frame>
    <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2)</measure>
    <time_frame>Two consecutive days of treatment</time_frame>
    <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14)</measure>
    <time_frame>Days 2-14 of fourteen consecutive days of treatment</time_frame>
    <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 7-14)</measure>
    <time_frame>Days 7-14 of fourteen consecutive days of treatment</time_frame>
    <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Statistical Analysis of TMC207 Maximum Plasma Concentration Following Dosing (C(Max)) on Days 1 and 14</measure>
    <time_frame>Day 1 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose) or Day 14 (0, 1, 3, 5, 6, 8, 12, 24, and 30 hour post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Statistical Analysis of TMC207 Time of Maximum Plasma Concentration (T(Max)) on Days 1 and 14</measure>
    <time_frame>Day 1 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose) or Day 14 (0, 1, 3, 5, 6, 8, 12, 24, and 30 hour post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Statistical Analysis of TMC207 Area Under the Concentration-time Curve Over the Dose Interval of 0 to 24 h (AUC(0-24)) on Day 1 and Day 14</measure>
    <time_frame>Day 1 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose) or Day 14 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>TMC207 700/500/400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC207 500/400/300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC207 400/300/200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC207 200/100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifafour e-275 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifafour e-275 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC207</intervention_name>
    <arm_group_label>TMC207 700/500/400</arm_group_label>
    <arm_group_label>TMC207 500/400/300</arm_group_label>
    <arm_group_label>TMC207 400/300/200</arm_group_label>
    <arm_group_label>TMC207 200/100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifafour e-275 mg</intervention_name>
    <arm_group_label>Rifafour e-275 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written, informed consent prior to all trial-related procedures including HIV
             testing.

          -  Male or female, aged between 18 and 65 years inclusive.

          -  Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.

          -  Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary
             TB.

          -  A chest X-ray picture which in the opinion of the Investigator is compatible with TB.

          -  Sputum positive on direct microscopy for acid-fast bacilli …(at least 1+ on the
             International Union Against Tuberculosis and Lung Disease (IUATLD)/World Health
             Organization (WHO) scale).

          -  Ability to produce an adequate volume of sputum as estimated from a spot assessment
             (estimated 10 ml or more overnight production).

          -  Females may participate if they are of non-childbearing potential, if they are using
             effective birth control methods and are willing to continue practicing birth control
             methods throughout treatment or if they are non-heterosexually active or willing to
             practice sexual abstinence throughout the treatment period or have a vasectomized
             partner (confirmed sterile). Therefore to be eligible for this study women of
             childbearing potential should either:1) use a double barrier method to prevent
             pregnancy (i.e. use a condom with either diaphragm or cervical cap) or 2) use hormonal
             based contraceptives in combination with a barrier contraceptive, or 3) use an
             intrauterine device in combination with a barrier contraceptive. They must also be
             willing to continue these contraception until 6 months after last study drug or 6
             months after discontinuation from study medication in case of premature
             discontinuation. (Note: Hormone-based contraception may not be reliable when taking
             TMC207; therefore, hormone-based contraceptives cannot be used by female patients to
             prevent pregnancy).

          -  Male patients must be willing to use a condom with spermicide when having heterosexual
             intercourse throughout treatment and until 1 month after last study drug
             administration or 1 month after discontinuation from study medication in case of
             premature discontinuation.

        Exclusion Criteria:

          1. Evidence of clinically significant metabolic, gastrointestinal neurological,
             psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the
             indication being studied).

          2. Known or suspected hypersensitivity to study medications (including any rifamycin
             antibiotics)

          3. Rifampicin-resistant and/or isoniazid-resistant bacteria detected with a sputum
             specimen collected within the pre-treatment period and tested at the study laboratory.

          4. Clinically significant evidence of extrathoracic TB (miliary TB, abdominal TB,
             urogenital TB, osteoarthritic TB, TB meningitis), as judged by the investigator.

          5. Current or past history of alcohol and/or drug use that, in the investigator's
             opinion, would compromise the participant's safety or compliance to the study protocol
             procedures.

          6. HIV infected patients:

               1. having a cluster of differentiation 4 (CD4)+ count &lt;300 cells/µL;

               2. or having received antiretroviral therapy medication within the last 90 days:

               3. or having received oral or intravenous antifungal medication within the last 90
                  days;

               4. or with an AIDS-defining opportunistic infection or malignancies (except
                  pulmonary TB).

          7. Significant cardiac arrhythmia requiring medication

          8. Having participated in other clinical studies with investigational agents within 8
             weeks prior to trial start.

          9. Patients with the following QT/corrected QT(QTc) interval characteristics at
             screening:

               1. Marked prolongation of QT/QTc interval, e.g., confirmed demonstration of QT
                  corrected for heart rate using Fridericia's method (QTcF) interval &gt;450 ms at
                  screening;

               2. History of additional risk factors for Torsade de Pointes, e.g., heart failure,
                  hypokalemia, family history of Long QT Syndrome;

               3. Use of concomitant medications that prolong the QT/QTc interval listed as
                  disallowed medication in Section 2.10.2;

               4. Pathological Q waves (defined as &gt;40ms or depth &gt;0.4-0.5mV);

               5. Evidence of ventricular pre-excitation;

               6. ECG evidence of complete or incomplete left bundle branch block or right bundle
                  branch block;

               7. Evidence of second or third degree heart block;

               8. Intraventricular conduction delay with QRS duration &gt;120ms;

               9. Bradycardia as defined by sinus rate &lt;50bpm

         10. Women who are pregnant or breastfeeding

         11. History and/or presence (or evidence) of neuropathy or epilepsy.

         12. Diabetics using insulin

         13. Poor general condition where any delay in treatment cannot be tolerated per discretion
             of Investigator.

         14. Previously received treatment with TMC207 as part of a clinical trial.

         15. Treatment received with any drug active against Mycobacterium tuberculosis within 3
             months prior to Visit 1.

         16. Any disease or conditions in which any of the medicinal products listed in the section
             pertaining to prohibited medications is used.

         17. Patients with the following toxicities at screening as defined by the enhanced
             Division of Microbiology and Infectious Disease (DMID) adult toxicity table (November
             2007):

               1. creatinine grade 2 or greater (&gt;1.5 times upper limit of normal [ULN]);

               2. lipase grade 3 or greater (&gt;2.0 x ULN);

               3. hemoglobin grade 4 (&lt;6.5 g/dL) except after discussion with the Medical Monitor;

               4. aspartate aminotransferase (AST) grade 4 (&gt;8.0 x ULN) to be excluded, grade 3
                  (≥3.0 x ULN) must be discussed with Medical Monitor;

               5. alanine aminotransferase (ALT) grade 4 (&gt;8.0 x ULN) to be excluded, grade 3 (≥3.0
                  x ULN) must be discussed with Medical Monitor;

               6. alkaline phosphatase (ALP) grade 4 (&gt;8.0 x ULN) to be excluded, grade 3 (≥3.0 x
                  ULN) must be discussed with Medical Monitor;

               7. total bilirubin grade 3 or greater (&gt;2.00 x ULN, or &gt;1.50 x ULN when accompanied
                  by any increase in other liver function test) to be excluded, grade 2 (&gt;1.50 x
                  ULN, or &gt;1.25 x ULN when accompanied by any increase in other liver function
                  test) must be discussed with the Medical Monitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Diacon</last_name>
    <role>Principal Investigator</role>
    <affiliation>TASK APPLIED SCIENCE, Karl Bremer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karl Bremer Hospital</name>
      <address>
        <city>Belville</city>
        <state>Cape Town</state>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <results_first_submitted>October 19, 2016</results_first_submitted>
  <results_first_submitted_qc>March 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2017</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bedaquiline</keyword>
  <keyword>Sirturo</keyword>
  <keyword>Early Bactericidal Activity</keyword>
  <keyword>EBA</keyword>
  <keyword>Pulmonary Tuberculosis</keyword>
  <keyword>TMC207</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bedaquiline</mesh_term>
    <mesh_term>Diarylquinolines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TMC207 100</title>
          <description>TMC207- 200 mg Day 1; and 100 mg Days 2-14</description>
        </group>
        <group group_id="P2">
          <title>TMC207 200</title>
          <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14.</description>
        </group>
        <group group_id="P3">
          <title>TMC207 300</title>
          <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14</description>
        </group>
        <group group_id="P4">
          <title>TMC207 400</title>
          <description>TMC207- 700 mg Day 1; 500 mg Day 2; and 400 mg Days 3-14</description>
        </group>
        <group group_id="P5">
          <title>Rifafour e-275 mg</title>
          <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TMC207 100</title>
          <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
        </group>
        <group group_id="B2">
          <title>TMC207 200</title>
          <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
        </group>
        <group group_id="B3">
          <title>TMC207 300</title>
          <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
        </group>
        <group group_id="B4">
          <title>TMC207 400</title>
          <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
        </group>
        <group group_id="B5">
          <title>Rifafour e-275 mg</title>
          <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="9.4"/>
                    <measurement group_id="B2" value="34.7" spread="18.1"/>
                    <measurement group_id="B3" value="31.4" spread="7.4"/>
                    <measurement group_id="B4" value="31.8" spread="10.9"/>
                    <measurement group_id="B5" value="26.1" spread="4.9"/>
                    <measurement group_id="B6" value="27" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Ethnic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meters (m)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.638" spread="0.082"/>
                    <measurement group_id="B2" value="1.677" spread="0.094"/>
                    <measurement group_id="B3" value="1.674" spread="0.082"/>
                    <measurement group_id="B4" value="1.660" spread="0.057"/>
                    <measurement group_id="B5" value="1.660" spread="0.087"/>
                    <measurement group_id="B6" value="1.662" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Day 1</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.0" spread="7.74"/>
                    <measurement group_id="B2" value="52.5" spread="7.55"/>
                    <measurement group_id="B3" value="52.7" spread="8.20"/>
                    <measurement group_id="B4" value="50.6" spread="5.96"/>
                    <measurement group_id="B5" value="49.1" spread="6.69"/>
                    <measurement group_id="B6" value="51.8" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.80" spread="2.988"/>
                    <measurement group_id="B2" value="18.63" spread="1.955"/>
                    <measurement group_id="B3" value="18.80" spread="2.754"/>
                    <measurement group_id="B4" value="18.36" spread="2.174"/>
                    <measurement group_id="B5" value="17.83" spread="2.018"/>
                    <measurement group_id="B6" value="18.77" spread="2.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline log10 colony forming units (CFU) of M. Tuberculosis per ml sputum</title>
          <units>log(10) CFU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.302" spread="0.697"/>
                    <measurement group_id="B2" value="6.001" spread="0.903"/>
                    <measurement group_id="B3" value="6.071" spread="1.087"/>
                    <measurement group_id="B4" value="6.625" spread="0.756"/>
                    <measurement group_id="B5" value="5.995" spread="1.018"/>
                    <measurement group_id="B6" value="6.199" spread="0.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline time to sputum culture positivity (TTP) in liquid culture media</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.8" spread="23.5"/>
                    <measurement group_id="B2" value="111.1" spread="30.6"/>
                    <measurement group_id="B3" value="115.7" spread="40.8"/>
                    <measurement group_id="B4" value="88.5" spread="10.8"/>
                    <measurement group_id="B5" value="106.7" spread="28.8"/>
                    <measurement group_id="B6" value="105.3" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).</title>
        <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
        <time_frame>Fourteen consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).</title>
          <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
          <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
          <units>log10CFU/ml/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040" spread="0.068"/>
                    <measurement group_id="O2" value="0.056" spread="0.051"/>
                    <measurement group_id="O3" value="0.077" spread="0.064"/>
                    <measurement group_id="O4" value="0.104" spread="0.077"/>
                    <measurement group_id="O5" value="0.112" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 7-14).</title>
        <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Since Day 7 is later than the node day, the rate of change for this outcome is equal to the slope at Day 14. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
        <time_frame>Days 7-14 of fourteen consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 7-14).</title>
          <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Since Day 7 is later than the node day, the rate of change for this outcome is equal to the slope at Day 14. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
          <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
          <units>log10CFU/ml/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.088"/>
                    <measurement group_id="O2" value="0.086" spread="0.048"/>
                    <measurement group_id="O3" value="0.098" spread="0.084"/>
                    <measurement group_id="O4" value="0.107" spread="0.082"/>
                    <measurement group_id="O5" value="0.046" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).</title>
        <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
        <time_frame>Days 2-14 of fourteen consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).</title>
          <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
          <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
          <units>log10CFU/ml/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.074"/>
                    <measurement group_id="O2" value="0.071" spread="0.047"/>
                    <measurement group_id="O3" value="0.088" spread="0.071"/>
                    <measurement group_id="O4" value="0.106" spread="0.078"/>
                    <measurement group_id="O5" value="0.046" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).</title>
        <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Since this range (Days0-2) is before the node day, the rate of change for this outcome is equal to the slope at Day 0. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
        <time_frame>Two consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).</title>
          <description>The rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group. The nodes (point of inflection, i.e. where slope changes) used in these bi-linear regressions, as determined by visual inspection, were Day 3.5. node. Throughout the analyses, the established node at Day 2.5 was used in the Rifafour e-275 arm. Since this range (Days0-2) is before the node day, the rate of change for this outcome is equal to the slope at Day 0. Note that to facilitate interpretation the sign of these slopes were reversed for log10CFU/ml.</description>
          <population>Because of insufficient data for bilinear regression, four patients were omitted from EBA(CFU) calculations.</population>
          <units>log10CFU/ml/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.168"/>
                    <measurement group_id="O2" value="-0.033" spread="0.128"/>
                    <measurement group_id="O3" value="0.015" spread="0.149"/>
                    <measurement group_id="O4" value="0.093" spread="0.136"/>
                    <measurement group_id="O5" value="0.413" spread="0.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14)</title>
        <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
        <time_frame>Fourteen consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14)</title>
          <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
          <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
          <units>hours/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="5.1"/>
                    <measurement group_id="O2" value="4.2" spread="3.1"/>
                    <measurement group_id="O3" value="4.9" spread="5.1"/>
                    <measurement group_id="O4" value="5.4" spread="3.4"/>
                    <measurement group_id="O5" value="14.3" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2)</title>
        <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
        <time_frame>Two consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2)</title>
          <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
          <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
          <units>hours/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.3"/>
                    <measurement group_id="O2" value="3.7" spread="4.3"/>
                    <measurement group_id="O3" value="4.1" spread="4.7"/>
                    <measurement group_id="O4" value="6.2" spread="3.3"/>
                    <measurement group_id="O5" value="27.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14)</title>
        <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
        <time_frame>Days 2-14 of fourteen consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14)</title>
          <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
          <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
          <units>hours/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="5.9"/>
                    <measurement group_id="O2" value="4.3" spread="3.1"/>
                    <measurement group_id="O3" value="5.1" spread="5.3"/>
                    <measurement group_id="O4" value="5.3" spread="3.5"/>
                    <measurement group_id="O5" value="11.5" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 7-14)</title>
        <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
        <time_frame>Days 7-14 of fourteen consecutive days of treatment</time_frame>
        <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
          </group>
          <group group_id="O5">
            <title>Rifafour e-275 mg</title>
            <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 7-14)</title>
          <description>The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated from the two slopes of the bi-linear (piece-wise) regression, for each treatment group.</description>
          <population>Because of insufficient data for bilinear regression, nine participants were omitted from TTP calculations.</population>
          <units>hours/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="11.2"/>
                    <measurement group_id="O2" value="4.8" spread="4.4"/>
                    <measurement group_id="O3" value="5.9" spread="7.2"/>
                    <measurement group_id="O4" value="4.4" spread="5.0"/>
                    <measurement group_id="O5" value="11.5" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Statistical Analysis of TMC207 Maximum Plasma Concentration Following Dosing (C(Max)) on Days 1 and 14</title>
        <time_frame>Day 1 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose) or Day 14 (0, 1, 3, 5, 6, 8, 12, 24, and 30 hour post-dose)</time_frame>
        <population>On Day 14, N=13 for TMC207 300 group and N=14 for TMC207 400 group due to early withdrawal of three participants</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1; and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14.</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; and 400 mg Days 3-14</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Statistical Analysis of TMC207 Maximum Plasma Concentration Following Dosing (C(Max)) on Days 1 and 14</title>
          <population>On Day 14, N=13 for TMC207 300 group and N=14 for TMC207 400 group due to early withdrawal of three participants</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C(max) Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1846.13" spread="613.55"/>
                    <measurement group_id="O2" value="2700.73" spread="858.54"/>
                    <measurement group_id="O3" value="3128.00" spread="1239.26"/>
                    <measurement group_id="O4" value="5386.67" spread="3069.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C(max) Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1553.27" spread="691.36"/>
                    <measurement group_id="O2" value="2884.67" spread="789.44"/>
                    <measurement group_id="O3" value="3902.31" spread="771.77"/>
                    <measurement group_id="O4" value="5178.57" spread="2663.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Statistical Analysis of TMC207 Time of Maximum Plasma Concentration (T(Max)) on Days 1 and 14</title>
        <time_frame>Day 1 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose) or Day 14 (0, 1, 3, 5, 6, 8, 12, 24, and 30 hour post-dose)</time_frame>
        <population>On Day 14, N=13 for TMC207 300 group and N=14 for TMC207 400 group due to early withdrawal of three participants</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1; and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14.</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; and 400 mg Days 3-14</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Statistical Analysis of TMC207 Time of Maximum Plasma Concentration (T(Max)) on Days 1 and 14</title>
          <population>On Day 14, N=13 for TMC207 300 group and N=14 for TMC207 400 group due to early withdrawal of three participants</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T(max) Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="1.80"/>
                    <measurement group_id="O2" value="5.20" spread="1.90"/>
                    <measurement group_id="O3" value="5.53" spread="0.83"/>
                    <measurement group_id="O4" value="5.67" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T(max) Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="1.19"/>
                    <measurement group_id="O2" value="4.60" spread="1.06"/>
                    <measurement group_id="O3" value="5.15" spread="1.46"/>
                    <measurement group_id="O4" value="5.29" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Statistical Analysis of TMC207 Area Under the Concentration-time Curve Over the Dose Interval of 0 to 24 h (AUC(0-24)) on Day 1 and Day 14</title>
        <time_frame>Day 1 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose) or Day 14 (0, 1, 3, 5, 6, 8, 12, and 24 hour post-dose)</time_frame>
        <population>On Day 14, N=13 for TMC207 300 group and N=14 for TMC207 400 group due to early withdrawal of three participants</population>
        <group_list>
          <group group_id="O1">
            <title>TMC207 100</title>
            <description>TMC207- 200 mg Day 1; and 100 mg Days 2-14</description>
          </group>
          <group group_id="O2">
            <title>TMC207 200</title>
            <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14.</description>
          </group>
          <group group_id="O3">
            <title>TMC207 300</title>
            <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14</description>
          </group>
          <group group_id="O4">
            <title>TMC207 400</title>
            <description>TMC207- 700 mg Day 1; 500 mg Day 2; and 400 mg Days 3-14</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Statistical Analysis of TMC207 Area Under the Concentration-time Curve Over the Dose Interval of 0 to 24 h (AUC(0-24)) on Day 1 and Day 14</title>
          <population>On Day 14, N=13 for TMC207 300 group and N=14 for TMC207 400 group due to early withdrawal of three participants</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24) Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18995.57" spread="6947.92"/>
                    <measurement group_id="O2" value="26619.51" spread="8453.09"/>
                    <measurement group_id="O3" value="31357.35" spread="10596.74"/>
                    <measurement group_id="O4" value="53179.27" spread="20699.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-24) Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18689.03" spread="4450.56"/>
                    <measurement group_id="O2" value="33314.07" spread="5780.02"/>
                    <measurement group_id="O3" value="50547.15" spread="11914.16"/>
                    <measurement group_id="O4" value="69069.64" spread="27062.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>49 days</time_frame>
      <desc>Adverse events were collected by the Investigator from the time a participant signed the Informed Consent Form until the end of follow-up visit (Day 49). Data reported are treatment-emergent adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>TMC207 100</title>
          <description>TMC207- 200 mg Day 1 and 100 mg Days 2-14</description>
        </group>
        <group group_id="E2">
          <title>TMC207 200</title>
          <description>TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14</description>
        </group>
        <group group_id="E3">
          <title>TMC207 300</title>
          <description>TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.</description>
        </group>
        <group group_id="E4">
          <title>TMC207 400</title>
          <description>TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14</description>
        </group>
        <group group_id="E5">
          <title>Rifafour e-275 mg</title>
          <description>Daily Doses: 30 to 37 kg, 2 tablets; 38 to 54 kg, 3 tablets; 55 to 70 kg, 4 tablets; 71 kg and over, 5 tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator or any Sub-Investigator shall submit any oral or written publication or abstract concerning this study to the Sponsor not less than thirty (30) days prior to submission to any journal, other publication or meeting, for review and removal of confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel E. Everitt, MD, Vice President and Senior Medical Officer</name_or_title>
      <organization>Global Alliance for TB Drug Development</organization>
      <phone>212-227-7540</phone>
      <email>Dan.Everitt@tballiance.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

